ReviewVision (Basel, Switzerland)2023
Non-Arteritic Anterior Ischemic Optic Neuropathy (NA-AION): A Comprehensive Overview.
Review in Vision (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis.JAMA ophthalmology · 2025Pooled it
- Ocular Manifestations of Metabolic Syndrome: A Systemic Vascular Phenotype.Diabetes, obesity & metabolism · 2026Review
- Non-Arteritic Anterior Ischemic Optic Neuropathy (NA-AION) and High-Risk Cardiovascular Events.Life (Basel, Switzerland) · 2026Article
- Psychiatric and eye disorders associated with use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs).Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Development of a predictive model for visual outcomes and risk factors of bilateral involvement for non-arteritic anterior ischemic optic neuropathy (NAION) in Chinese patients.Eye and vision (London, England) · 2026Article
- Machine Learning Integrating SERF-MEG and VEP for Diagnosis and Differential Diagnosis of Optic Neuropathies.Bioengineering (Basel, Switzerland) · 2026Article
- SERF-MEG as a Functional Biomarker of Optic Nerve Injury: Agreement and Correlation with Visual Evoked Potentials.Bioengineering (Basel, Switzerland) · 2026Article
- Diabetic Retinopathy and Current Treatment Approaches: From Pathogenesis to Extracellular Vesicle-Based Therapies.International journal of molecular sciences · 2026Review
- Color Doppler ultrasound study: assessing orbital hemodynamics and vascular changes in mucosal lichen planus.BMC research notes · 2026Article
- Tropomyosin-Related Kinase Receptor Type B Agonism in Geographic Atrophy-The Translational Challenges from Preclinical Data to a First-in-Human Trial.Ophthalmology science · 2026Article
- Decoding Visual Pathway Dysfunction with SERF-MEG: A Study in Patients with Optic Neuropathy.Bioengineering (Basel, Switzerland) · 2026Article
- Ocular complications from glucagon-like peptide-1 receptor agonists: Clinical evidence, potential mechanisms, and clinical recommendations.Journal of the Chinese Medical Association : JCMA · 2026Review
- Article
- IL-1-mediated vitreous inflammation as an early indicator of retinal ganglion cell loss following acute optic nerve injury.Journal of neuroinflammation · 2026Article
- The Effects of GLP-1 Receptor Agonists on Retinal Microvascular Alterations.Biomedicines · 2026Review
- The role of prostanoids in the retina and optic nerve in health and disease.Progress in retinal and eye research · 2026Review
- Evaluating the Safety Profile of Glucagon-Like Peptide-1 Receptor Agonists: Adverse Events and Clinical Recommendations.Journal of obesity & metabolic syndrome · 2026Review
- Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP-1 Receptor Agonists.Annals of clinical and translational neurology · 2026Article
- Perioperative ischemic optic neuropathy: a comprehensive review of anesthetic implications, hemodynamic pathophysiology, and risk stratification.International ophthalmology · 2026Review
- Clues to prognosis in anterior ischemic optic neuropathy: an optical coherence tomography angiography study.International journal of ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-arteritic anterior ischemic optic neuropathy (NA-AION) represents one of the most important causes of blindness or severely impaired vision in middle-aged and elderly people. Unilateral optic disc edema and abrupt, painless vision loss are its defining features. It is commonly assumed that NA-AION is caused by an ischemic infarction of the optic nerve head, and, although the exact pathogenesis is still unknown, several risk factors and comorbidities associated with its development have been found. NA-AION occurs generally in patients older than 50 years who have small optic discs and vasculopathy risk factors. Even though numerous treatment options have been proposed, no available effective medical or surgical therapy or prophylactic measure for NA-AION currently exists. The purpose of present-day therapeutic strategies is therefore to identify and possibly control any underlying modifiable risk factors, aiming to prevent the development of new NA-AION episodes in the affected and fellow eye. A thorough assessment of NAION, including its history, epidemiology, etiology, pathophysiology, risk factors, associated comorbidities, clinical findings, diagnostic tests, treatment choices, prognosis, and future research, is the goal of this work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.